Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis

Alexis Ogdie (alexis.ogdie@uphs.upenn.edu)  
University of Pennsylvania

Martin Rozycki  
HVH Precision Analytics, LLC

Theresa Amdt  
HVH Precision Analytics, LLC

Cheng Shi  
Novartis Pharmaceuticals Corp

Nina Kim  
The University of Texas at Austin

Peter Hur  
Novartis Pharmaceuticals Corp

Research article

Keywords: spondyloarthropathies, epidemiology, biological therapies, DMARDs, quality of health care

DOI: https://doi.org/10.21203/rs.3.rs-503530/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The occurrence of health events preceding a psoriatic arthritis (PsA) diagnosis may serve as predictors of diagnosis. We sought to assess patients’ real-world experiences in obtaining a PsA diagnosis.

Methods: This retrospective cohort study analyzed MarketScan claims data from January 2006 to April 2019. Included were adult patients with ≥2 PsA diagnoses (ICD-9-CM/ICD-10-CM) ≥30 days apart with ≥6 years of continuous enrolment before PsA diagnosis. Controls were matched 2:1 to patients with PsA. Health events (diagnoses and provider types) were analyzed before PsA diagnosis and additionally stratified by presence of psoriasis.

Results: Of 13,661 patients, those with PsA had an increased history of coding for arthritis and dermatologic issues (osteoarthritis [48% vs 22%], rheumatoid arthritis [18% vs 2%], and psoriasis [61% vs 2%]) vs those without PsA. Diagnoses of arthritis, axial symptoms, and tendonitis/enthesitis increased over time preceding PsA diagnosis; notably, a sharp rise in psoriasis diagnoses was observed 6 months before PsA diagnosis. Rheumatology consults were more common immediately preceding a PsA diagnosis. Dermatologists were unlikely to code for arthritis and musculoskeletal issues, while rheumatologists were unlikely to code for psoriasis; general practitioners focused on axial and musculoskeletal symptoms. PsA was most commonly diagnosed by rheumatologists (40%), general practitioners (22%), and dermatologists (7%).

Conclusions: Rheumatologists, general practitioners, and dermatologists diagnosed two-thirds of patients with PsA. Musculoskeletal symptoms were common preceding a PsA diagnosis. Greater awareness of patterns of health events may alert healthcare providers to suspect a diagnosis of PsA.

Background

Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the skin and musculoskeletal system with various manifestations [1, 2]. PsA is typically characterized by 6 clinical domains: axial disorders, nail disease, skin disease, peripheral disease, enthesitis, and dactylitis, either alone or in combination [3]. PsA is also associated with many comorbidities [4] that collectively impair patients’ quality of life, overall function, and clinical burden [5]. A timely diagnosis of PsA is critical because a delay in diagnosis negatively impacts patient outcomes [6, 7].

Unfortunately, diagnostic delay is common in PsA. In a cross-sectional study of 203 participants with self-reported PsA in the United States, approximately one-third received their diagnosis within 6 months to 4 years, while another one-third had to wait for > 5 years [8]. These participants also consulted with numerous healthcare providers prior to receiving their diagnosis. A 6-month delay from PsA symptom onset to initial rheumatology consult may lead to joint erosion and damage [9, 10]. An increased awareness of the heterogeneity of PsA symptoms and diagnostic barriers may lead to a timely diagnosis.
Our study aimed to assess patient experiences in the period prior to diagnosis of PsA using administrative claims data. We described and analyzed health events (ie, diagnosis codes and provider types consulted by patients) prior to PsA diagnosis to better understand a patient’s journey to diagnosis.

**Materials And Methods**

**Data source**

This retrospective cohort study used administrative claims data from patients in the Truven MarketScan research databases [11] from January 2006 to April 2019. Comprising 3 core claims databases (Commercial, Medicare Supplemental, and Medicaid), the MarketScan records represent one of the largest collections of deidentified US patient data available for healthcare research, with > 263 million covered lives in 2020. Data sets include the inpatient, outpatient, and outpatient prescription drug experience of several million employees and their dependents (annually), covered under a variety of fee-for-service and capitated health plans, including exclusive provider organizations, preferred provider organizations, point-of-service plans, indemnity plans, and health maintenance organizations. These databases provide detailed cost, utilization, and outcomes data for healthcare services performed in both inpatient and outpatient settings. The medical claims are linked to outpatient prescription drug claims and person-level enrolment data using unique enrollee identifiers.

**Data variables and study population**

Variables considered in this study included health events and demographics extracted entirely from the claims database; no prefiltering of any variable category was performed. To be included in our study, patients with PsA must have received 2 diagnoses of PsA, specified by the International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM), ≥ 30 days apart; patients were aged ≥ 18 years at diagnosis and had ≥ 6 years of continuous enrolment prior to PsA diagnosis. The following diagnosis codes were included: 696.0 (psoriatic arthropathy), L40.50 (arthropathic psoriasis, unspecified), L40.51 (distal interphalangeal psoriatic arthropathy), L40.52 (psoriatic arthritis mutilans), L40.53 (psoriatic spondylitis), L40.54 (psoriatic juvenile arthropathy), and L40.59 (other psoriatic arthropathy). Controls (those without a diagnosis of PsA) were matched 2:1 to patients with PsA for age, sex, insurance, and enrolment duration (ie, the index date for controls was the end of the matched 6-year period that terminated in “no PsA”).

The data analyzed in this study included the demographic variables mentioned above as well as data on health events. A health event was defined as any health service provided to a patient in the preindex period, derived from their medical and pharmacy claims history. Health events included PsA diagnosis codes (ICD-9-CM and ICD-10-CM) and specialty physician types (eg, general practitioners, dermatologists, rheumatologists) as enumerated by the MarketScan databases. Information on health events was captured every 6 months for the 6 years prior to PsA diagnosis. Results were also stratified by the presence of psoriasis vs no psoriasis prior to PsA diagnosis.
This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practices of the International Society for Pharmacoepidemiology, the Strengthening the Reporting of Observational Studies in Epidemiology guidelines, and the ethical principles in the Declaration of Helsinki. All database records were fully compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996. As this study is a retrospective analysis of deidentified claims data in compliance with US patient confidentiality requirements and did not involve the collection, use, or transmittal of individually identifiable data, institutional review board approval was not required to conduct this study.

Results

Patient demographics and diagnosis history

Of > 265 million patients in the MarketScan databases, 280,311 patients had ≥ 1 diagnosis of PsA and 174,524 patients had ≥ 2 diagnoses of PsA 30 days apart, of whom 172,119 patients were aged ≥ 18 years at the index date. Of these, a final cohort of 13,661 patients had ≥ 6 years of continuous enrolment in the database, fulfilling the criteria for inclusion in the study. The mean age was 55.8 years and 60.2% were women; baseline demographics of patients diagnosed with PsA and non-PsA controls are shown in Table 1.
Table 1  
Baseline demographics of patients diagnosed with PsA and non-PsA controls.

| Characteristic     | Patients With PsA (N = 13,661) | Non-PsA Controls\(^a\) (N = 26,729) |
|--------------------|---------------------------------|------------------------------------|
| Age, mean (SD), years | 55.8 (12.6)                   | 55.9 (12.7)                        |
| Female, %          | 60.2                           | 60.4                               |
| Insurance type, %  |                                |                                    |
| Commercial         | 78.6                           | 78.6                               |
| Medicaid           | 15.1                           | 15.3                               |
| Medicare           | 6.3                            | 6.1                                |
| US geographical region, % |                              |                                    |
| Midwest            | 21.7                           | 30.0                               |
| Northeast          | 15.2                           | 48.7                               |
| South              | 43.6                           | 11.9                               |
| West               | 12.9                           | 3.2                                |
| Unknown            | 6.6                            | 6.2                                |

\(^a\) Controls were matched 2:1 to patients with PsA for age, sex, insurance, and enrolment duration.

Compared with controls, patients with PsA received more codes for arthritis and skin issues, including osteoarthritis (OA; 48% vs 22%), rheumatoid arthritis (18% vs 2%), inflammatory polyarthritis (IA; 18% vs 1%), and psoriasis (61% vs 2%) (Fig. 1A). Patients with PsA without a prior diagnosis of psoriasis received more codes for other forms of arthritis compared with those with PsA and psoriasis, including OA (52% vs 45%), rheumatoid arthritis (27% vs 13%), and IA (26% vs 12%) (Fig. 1B).

Patients received a variety of diagnosis codes for their condition prior to the first PsA diagnosis code, suggestive of misdiagnosis. These patients received many symptom codes over the 6-year period prior to PsA diagnosis (Fig. 2). For many patients, the number of diagnoses of different types of arthritis, axial symptoms, and tendonitis/enthesitis steadily increased over time prior to the PsA diagnosis. Prior to PsA diagnosis, a sharp rise in the number of psoriasis diagnoses was observed; increases in the number of diagnoses of OA and IA were also noted.

**Physician specialty analysis**
General practitioners, rheumatologists, and dermatologists were seen with increasing frequency approaching diagnosis (Fig. 3). A large proportion of patients received medical care from general practitioners in the 6 years preceding the PsA diagnosis. In this 6-year window, patients were symptomatic and received various non-PsA diagnosis codes for their condition. A sizable and abrupt increase in the number of rheumatology visits was observed immediately before the diagnosis of PsA. Large increases were also observed for dermatologist and orthopedic surgeon visits.

Diagnoses made prior to the diagnosis of PsA differed by the type of provider that patients saw (Fig. 4). Dermatologists were less likely than other providers to enter codes for arthritis and musculoskeletal issues, while rheumatologists were unlikely to code for psoriasis but had a fairly even distribution across different types of arthritis. General practitioners focused more on axial symptoms and nonspecific musculoskeletal manifestations than arthritis diagnoses. PsA was most commonly diagnosed by rheumatologists (40%) but was diagnosed in 22% and 7% of cases by general practitioners and dermatologists, respectively (Fig. 5).

Discussion

In this study, we analyzed occurrences of health events (ie, diagnosis codes and types of healthcare provider seen by patients) using the MarketScan research databases prior to the diagnosis of PsA to better comprehend a patient’s journey in obtaining a PsA diagnosis. Overall, nonspecific musculoskeletal manifestations and non-PsA diagnoses were common up to 6 years before the diagnosis of PsA compared with controls without PsA. The diagnoses and codes entered prior to PsA diagnosis varied by provider type. Rheumatologists, general practitioners, and dermatologists accounted for the diagnoses of two-thirds of patients with PsA.

Timely referral of a patient with potential PsA for rheumatology evaluation is critical to improving outcomes for patients with PsA, and this been recognized for some time [9, 12, 13]. The ability to identify PsA symptoms early in the disease course, in addition to recognizing specific trends and patterns in a patient’s pursuit for diagnosis, may permit prompt referral to appropriate specialists, leading to an earlier diagnosis of PsA. These health events may serve as potential predictors of a PsA diagnosis with regard to the many diagnoses received and healthcare providers seen. Identifying the subset of the patient population for screening and referral may be additionally useful to avoid overwhelming rheumatology healthcare providers with high volumes of patients with musculoskeletal symptoms.

Compared with controls, patients with PsA in our study received a variety of additional non-PsA diagnosis codes, suggestive of PsA symptom build-up, in the 6 years preceding diagnosis. An analysis of administrative data in Canada similarly reported a build-up of musculoskeletal symptoms as early as 5 years prior to the diagnosis of PsA [14]. Patients manifesting these symptoms have well-documented difficulties (“unable to do” or “with much difficulty”) with various daily tasks, including the inability to bend down to pick up items from the floor or to walk on flat ground [15]. These, in combination with other
negative psychological, social, and economic impacts, contribute significantly to the overall burden of
disease and poor quality of life [16–19].

In addition, an abrupt increase in the number of psoriasis diagnoses was observed in our cohort
preceding the diagnosis of PsA. Although more than two-thirds of patients with PsA develop
dermatologic lesions prior to joint and musculoskeletal manifestations, the symptoms are not often
recognized as related to each other [15, 20, 21]. A study comprising 5604 patients with psoriasis or PsA
from the National Psoriasis Foundation survey panels reported that almost 70% of patients sought
medical help from 1 to 2 healthcare providers and 25% saw ≥ 3 providers within 2 years prior to the
survey before receiving a diagnosis of psoriasis [22]. Because the diagnosis journey for psoriasis may
portend a PsA diagnosis [23, 24], dermatologists are in a prime position to detect PsA early and rapidly
refer patients to rheumatology. Other studies have reported the presence of subclinical inflammation in
the joints and entheses of patients with psoriasis without a diagnosis of PsA [25, 26]. Subclinical PsA
may be regarded as a stage of the progression of psoriatic disease, characterized by joint inflammation
and/or morphological changes detectable by imaging modalities; up to 50% of all patients with psoriasis
may have symptoms suggestive of but not yet diagnosable as PsA [15, 20, 21, 27]. Undiagnosed PsA is
commonly observed in dermatology offices [28, 29] and has been recognized in almost one-third of
patients with psoriasis [24, 29–32]. Patients with psoriasis presenting with PsA manifestations,
comprising arthritis, enthesitis, dactylitis, nail disease, and spondylitis, should be evaluated for PsA [33].

Collectively, our study may indicate an opportunity for earlier detection of PsA as characterized by
nonspecific musculoskeletal manifestations and skin symptoms and suggests that these
musculoskeletal manifestations may be undercoded or underrecognized in clinical practice [27]; improved
outcomes have been observed among patients who were promptly treated after receiving a diagnosis of
PsA [12, 13, 34]. In creating algorithms using electronic medical records or administrative (ie, insurance)
databases to identify patients who may have early PsA, data scientists need to consider that the
diagnosis pathways may differ from patient to patient, depending on the sequence of provider specialties
consulted by the patient.

Approaching PsA diagnosis, general practice, rheumatology, and dermatology visits were much more
frequent, suggesting the need for patient education in recognizing symptoms of arthritic conditions. A
delay in diagnosis due to initial medical consults with general practitioners and other nonrheumatology
healthcare providers is well recognized [8, 15, 17]. An integrated, multidisciplinary method is critical for
comprehensive medical care for patients with PsA. Rheumatologists and dermatologists are in an ideal
position to mediate collaborations with other healthcare providers and patient advocacy and support
groups for the design of a patient-centric intervention and treatment strategy [35, 36]. An improvement in
skin and joint symptoms was observed in more than half of patients with psoriasis and PsA after
treatment modifications facilitated by rheumatologists and dermatologists [35, 37]. However, as the
number of rheumatologists is predicted to decline by 30% by the year 2030 [38], more innovative
approaches to patient care are needed. Integrating the use of technology, such as software that
calculates composite targets based on both physician- and patient-reported outcomes to determine
disease activity status may be implemented [3]. Validated screening instruments may also be used [39–41], along with patient education and referral guidelines for general practitioners [36, 42]. The future development of applications that tabulate risk or likelihood of disease based on patient data may be a useful undertaking. A more patient-centric disease management method may be implemented with the use of currently available diagnostic tools, such as electronic applications allowing the upload of patient-reported outcomes prior to doctor visits [3]. This may help increase patient awareness of symptoms, enhance self-management, and improve patient-provider communication; the healthcare provider would enter notes from the visit into the same software.

There are limitations with our study that should be considered when interpreting the findings. As with any analysis of claims-based data, miscoding by healthcare providers may have occurred; however, the inclusion of patients with PsA who had received 2 diagnosis codes, instead of only 1 diagnosis code, may decrease the likelihood of miscoding or misdiagnosis. Additionally, some healthcare services may not be included in claims databases, leading to the underestimation of overall disease and economic burden. *ICD-9-CM* and *ICD-10-CM* codes are used for billing and may not reflect an accurate diagnosis, and there was no independent confirmation of patient diagnoses. This analysis is informative, regardless, by evaluating the real-world diagnostic experience of a large number of patients.

**Conclusions**

In summary, this study aimed to increase understanding of the patient journey to a diagnosis of PsA and underscores the need for prompt and improved diagnostic approaches from a health systems perspective. An overall prevalence of skin and nonspecific musculoskeletal manifestations, in addition to consultations with various types of healthcare providers, may collectively serve as predictors of PsA. Greater awareness of patterns or trends of health events as seen in our study may alert general practitioners and other healthcare providers in primary care settings to suspect a diagnosis of PsA among their patients. From a research standpoint, patients displaying these predictors may be followed to monitor for PsA development; future analyses will examine sequence of health events as predictors of PsA diagnosis. Using such algorithms may also help raise a differential diagnosis that the physician may not have thought of otherwise. As PsA is associated with considerable healthcare costs [43], the number of non-PsA diagnoses, potentially suggestive of misdiagnoses, and healthcare visits across different types of providers suggest the increased utilization of healthcare resources. The clinical and economic burden associated with PsA will most likely impact disease management and medical and pharmacy policy formulation. Increased awareness and understanding of diagnostic barriers may lead to timelier diagnosis, cost savings, and appropriate intervention to improve outcomes.

**Abbreviations**

IA, inflammatory polyarthritis; ICD-9-CM and ICD-10-CM, *International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification*; OA, osteoarthritis; PsA, psoriatic arthritis.
Declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practices of the International Society for Pharmacoepidemiology, the Strengthening the Reporting of Observational Studies in Epidemiology guidelines, and the ethical principles in the Declaration of Helsinki. All database records were fully compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996. As this study is a retrospective analysis of deidentified claims data in compliance with US patient confidentiality requirements and did not involve the collection, use, or transmittal of individually identifiable data, institutional review board approval was not required to conduct this study. Informed consent to participate was not applicable.

Consent for publication

Not applicable

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Competing interests

A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Data Bank), and Novartis (FORWARD Data Bank). M. Rozycki and T. Arndt were employees of HVH Precision Analytics at the time of this analysis. G. Shen and P. Hur are employees of Novartis Pharmaceuticals Corporation. N. Kim was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health, providing services to Novartis Pharmaceuticals Corporation, at the time of this analysis.

Funding

This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Authors’ contributions

All authors contributed to the study design, data analysis, and manuscript preparation.

Acknowledgments

Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ.
References

1. Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):569-79.
2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-70.
3. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum. 2016;68(5):1060-71.
4. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118-26.
5. Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, et al. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. Int J Rheum Dis. 2017;20(5):589-96.
6. McHugh NJ. Early Psoriatic Arthritis. Rheumatic diseases clinics of North America. 2015;41(4):615-22.
7. Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Mavnerakis E. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun. 2017;76:21-37.
8. Ogdie A, Nowell WB, Applegate E, Gavigan K, Venkatachalam S, de la Cruz M, et al. Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States. BMC Rheumatol. 2020;4:2.
9. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045-50.
10. Gottlieb AB, Mease PJ, Mark Jackson J, Eisen D, Amy Xia H, Asare C, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat. 2006;17(5):279-87.
11. Truven Health Analytics. IBM MarketScan Research Databases for Life Sciences Researchers. 2020. https://www.ibm.com/products/marketscan-research-databases/databases
12. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152-4.
13. Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407-13.
14. Eder L, Tu K, Rosen CF, Alhusayen R, Cheng SY, Young J, et al. Health care utilization for musculoskeletal issues during the pre-diagnosis period in psoriatic arthritis - a population-based study. Arthritis Care Res (Hoboken). Published on 2020 January 21. doi:10.1002/acr.24146
15. Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91-102.

16. Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, et al. Determinants of patient-physician discordance in global assessment in psoriatic arthritis: a multicenter European study. Arthritis Care Res (Hoboken). 2017;69(10):1606-11.

17. Betteridge N, Boehncke WH, Bundy C, Gossec L, Gratacós J, Augustin M. Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol. 2016;30(4):576-85.

18. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349-56.

19. Bergman M, Lundholm A. Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis. Arthritis Res Ther. 2017;19(1):63.

20. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87-97.

21. Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153-66.

22. Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol. 2013;149(6):717-21.

23. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-68.

24. Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242-8.

25. Mathew AJ, Bird P, Gupta A, George R, Danda D. Magnetic resonance imaging (MRI) of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis. Clin Rheumatol. 2018;37(2):383-8.

26. Eder L, Jayakar J, Thavaneswaran A, Haddad A, Chandran V, Salonen D, et al. Is the MAdrid Sonographic Enthesitis Index useful for differentiating psoriatic arthritis from psoriasis alone and healthy controls? J Rheumatol. 2014;41(3):466-72.

27. Eder L, Polachek A, Rosen CF, Chandran V, Cook R, Gladman DD. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol. 2017;69(3):622-9.

28. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national
29. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736-40.

30. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-35.

31. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040-7.

32. Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, et al. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. J Eur Acad Dermatol Venereol. 2019;33(5):886-92.

33. Bagel J, Schwartzman S. Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists. Am J Clin Dermatol. 2018;19(6):839-52.

34. Tillett W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis. 2013;72(8):1358-61.

35. Haberman R, Perez-Chada LM, Merola JF, Scher J, Ogdie A, Reddy SM. Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics. Curr Rheumatol Rep. 2018;20(12):76.

36. Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, et al. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken). 2014;66(12):1759-66.

37. Cobo-Ibáñez T, Villaverde V, Seoane-Mato D, Muñoz-Fernández S, Guerra M, Del Campo PD, et al. Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol Int. 2016;36(2):221-9.

38. di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken). 2013;65(1):141-7.

39. Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469-74.

40. Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68(4):497-501.

41. Tom BD, Chandran V, Farewell VT, Rosen CF, Gladman DD. Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). J Rheumatol. 2015;42(5):841-6.
42. Villeneuve E, Nam JL, Bell MJ, Deighton CM, Felson DT, Hazes JM, et al. A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Postgrad Med J. 2013;89(1050):231-40.

43. Merola JF, Herrera V, Palmer JB. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. Clin Rheumatol. 2018;37(10):2751-61.

Figures
Figure 1

Diagnosis codes in the 6 years prior to PsA diagnosis among (A) patients with PsA vs controls and (B) patients with PsA with prior vs no prior psoriasis diagnosis. GERD gastroesophageal reflux disease; mSK musculoskeletal; NOS not otherwise specified; PsA psoriatic arthritis. a Skin comprises 43 codes, including dermatitis, rash, acne, and keratosis. b Axial codes include >50 codes relating to axial disorders and syndromes and includes codes for spondylopathy, backache, and disc disorders. c Arthritis codes...
include chronic postrheumatic arthropathy (714.4); synovitis and tenosynovitis, unspecified (727.00); synovitis and tenosynovitis in diseases classified elsewhere (727.01); and secondary multiple arthritis (M153).

Figure 2

Cumulative patient journey through different diagnoses in the 6 years prior to PsA diagnosis. IA inflammatory polyarthritis; mSK musculoskeletal; NOS not otherwise specified; OA osteoarthritis; PsA psoriatic arthritis; RA rheumatoid arthritis; SpA spondyloarthritis.
Figure 3

Cumulative patient journey through different providers in the 6 years prior to PsA diagnosis. PsA psoriatic arthritis.
Figure 4

Coding patterns by specialty—fractions by specialty in the 6 years prior to PsA diagnosis. DCM Doctor of Chiropractic Medicine; GERD gastroesophageal reflux disease; IA inflammatory polyarthritis; mSK musculoskeletal; NOS not otherwise specified; OA osteoarthritis; PsA psoriatic arthritis; RA rheumatoid arthritis.
Figure 5

Distribution of physicians who diagnosed patients with PsA. PsA psoriatic arthritis. a Other comprises >50 providers from other disciplines, including pathology, radiology, endocrinology, and ophthalmology.